High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (AHSCT) is considered the standard therapy for patients with relapsed lymphoma. The aim of our study is the comparison of mitoxantrone-melphalan and BEAM (carmustine, etoposide, cytarabin and melphalan) conditioning regimens before autologous hematopoietic stem cell transplant in patients with lymphoma. This study has been performed in a retrospective manner. Hundred and two patients with relapsed/refractory Hodgkin lymphoma (n = 35) and non-Hodgkin lymphoma (n = 67) who underwent high-dose treatment followed by AHSCT at Memorial Sisli Hospital between 2013 and 2018 were evaluated. We retrieved data on patient demographics, disease status and post AHSCT outcomes. For conditioning regimen 52 patients received mitoxantrone (60 mg/m² × 1 day) and melphalan (180 mg/m² × 1 day) and 50 patients received BEAM (carmustine at 300 mg/m² × 1 day, etoposide at 200 mg/m² × 4 days, cytarabine at 2 × 200 mg/m² × 4 days and melphalan at 140 mg/m² × 1 day). The median age was 45 (18–73) years at the time of the diagnosis. No significant difference was observed in baseline characteristics between groups, including the disease control and previous therapies. Prior to high-dose chemotherapy, 79.4% of the patients were in complete remission (CR) and 20.6% was in partial remission (PR). With a median follow up of 30.5 months (range: 1–70 months) for the whole cohort, even though the OS was similar in both groups (86% ± 2.4 vs. 84% ± 3.2; p = 0.85), the PFS was noted to be superior among those who received conditioning with BEAM protocol (55% ± 3.7) compared to those with mitoxantrone-melphalan (30.6% ± 2.8; p = 0.006). In conclusion, we demonstrated that the BEAM regimen is an effective high-dose chemotherapy for lymphoma patients before AHSCT. Nevertheless mitoxantrone-melphalan regimen is also an alternative to the BEAM regimen.

高剂量化疗后进行自体造血干细胞移植（AHSCT）被认为是复发性淋巴瘤患者的标准治疗方法。我们研究的目的是比较淋巴瘤患者自体造血干细胞移植前的米托蒽醌-马法兰和 BEAM（卡莫司汀、依托泊苷、阿糖胞苷和马法兰）预处理方案。这项研究是以回顾性方式进行的。对 2013 年至 2018 年间在纪念西西里医院接受高剂量治疗并随后接受 AHSCT 的 102 名复发/难治性霍奇金淋巴瘤 (n = 35) 和非霍奇金淋巴瘤 (n = 67) 患者进行了评估。我们检索了有关患者人口统计、疾病状况和 AHSCT 后结果的数据。对于预处理方案，52 名患者接受米托蒽醌（60 mg/m ² × 1 天）和美法仑（180 mg/m ² × 1 天），50 名患者接受 BEAM（卡莫司汀 300 mg/m ² × 1 天，依托泊苷 200 mg） /m ² × 4 天，阿糖胞苷 2 × 200 mg/m ² × 4 天，马法兰 140 mg/m ² × 1 天）。诊断时的中位年龄为 45 (18-73) 岁。各组之间的基线特征（包括疾病控制和既往治疗）没有观察到显着差异。在大剂量化疗前，79.4%的患者处于完全缓解（CR）状态，20.6%处于部分缓解（PR）状态。整个队列的中位随访时间为 30.5 个月（范围：1-70 个月），尽管两组的 OS 相似（86% ± 2.4 对比 84% ± 3.2； p = 0.85），但 PFS 为注意到在接受 BEAM 协议调节的患者中表现更佳（55% ± 3.7) 与米托蒽醌-美法仑治疗相比 (30.6% ± 2.8; p = 0.006)。总之，我们证明 BEAM 方案是淋巴瘤患者 AHSCT 前有效的高剂量化疗。尽管如此，米托蒽醌-马法兰方案也是 BEAM 方案的替代方案。